Developer docs
API playgroundTry for free, no card

Search company profiles

Phyto Partners

Full company profile

uuid0002m49

Namestring
Phyto Partners
Legal namestring
Phyto Partners, LLC
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Phyto Partners is a Boca Raton, Florida-based venture capital firm founded in 2015 that manages two sector-focused funds serving accredited investors. The Phyto Cannabis Fund, launched in June 2015, deploys debt and equity capital into privately held companies across the cannabis value chain, including ancillary businesses in education, branded products, agriculture technology, point-of-sale software, and biotechnology. The firm has invested in approximately 30 distinct portfolio companies since inception and has produced multiple liquidity events including the public listings of Agrify (2019) and Greenlane (2020), the 2019 exit of Skylight Health, and the 2023 exit of Marijuana Doctor.

In 2021, Phyto extended its cannabis investment playbook into the emerging psychedelic and brain health sector through the launch of the Phyto Psyche Fund. The Psyche Fund targets companies developing mental health therapeutics, research tools, and ancillary services across the neurowellness value chain, with portfolio holdings spanning companies such as Wonder Sciences, Healing Maps, Mindstate Design, Muse, Healing REIT, Wondermed, and Firefly Neuro (which went public on NASDAQ under ticker AIFF in 2024).

The firm's business model is the standard venture capital model: management fees on committed capital plus carried interest on exits. Phyto differentiates through a 'more than a check' approach, providing portfolio companies with strategic support, business development assistance, introductions to customers, investors, and M&A targets, and facilitating portfolio synergies. Deal sourcing relies on proprietary industry networks and a 6-9 month due diligence framework designed for the regulatory complexity of cannabis and psychedelics. The firm operates with a lean team (1-10 employees), is structured as an LLC, and is led by Managing Partner Larry Schnurmacher with Partner Cody Shandraw, Senior Analyst Aaron Raub, Managing Director Brett Finkelstein, and CFO Gary Rubin.

Short descriptiontext

Phyto Partners is a venture capital firm managing two sector-focused funds—a Cannabis Fund (since 2015) and a Psyche Fund (psychedelics, since 2021)—that deploy debt and equity capital into privately held companies for accredited investors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBoca Raton, United States
HQ citystring
Boca Raton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cannabis venture capital, psychedelic investment fund, early-stage equity funding, venture fund management, neurowellness investing
NAICS code1 code
  • Other Investment Pools and Funds5259
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital Fund Management
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1VC Fund Management
TypeSubscription Recurring
Description

Phyto Partners generates revenue through management fees and carried interest (performance fees) from their venture capital funds. The firm manages the Phyto Cannabis Fund and Phyto Psyche Fund, deploying capital into portfolio companies and earning returns on successful exits.

phytopartners.com
2Portfolio Company Equity
TypeTransaction Fee
Description

The firm takes equity stakes in portfolio companies, generating returns through exits via M&A, public listings, or other liquidity events. Notable exits include Marijuana Doctor (2023), Skylight Health (2019), and Greenlane (2020 public listing), as well as Agrify public listing in 2019.

phytopartners.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Accredited investor VC fund participation
ModelOtherBilling cadenceMulti-year contract
Notes

Fund terms, minimum investments, and fee structures are not publicly disclosed. Available to accredited investors only.

phytopartners.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1Phyto Psyche Fund
Description

Psychedelic-focused venture capital fund targeting neurowellness and brain health companies

phytopartners.com
+1 more record
Core offering1 text field

Phyto Partners is a venture capital firm that manages and deploys capital from accredited investors into privately held cannabis and psychedelic companies. It operates two professionally managed funds—the Cannabis Fund (active since June 2015, with 30 portfolio companies) and the Phyto Psyche Fund (psychedelic-focused)—providing debt and equity capital, strategic support, business development, and industry network access to portfolio companies across the cannabis and emerging neurowellness value chains.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 30 portfolio companies funded since June 2015
+2 more records
Product overview1 text field

Phyto Partners is a venture capital firm operating two distinct funds: the Cannabis Fund (launched June 2015) and the Phyto Psyche Fund (psychedelic-focused). The Cannabis Fund provides debt and equity capital to privately held cannabis companies across the value chain, including ancillary businesses in education, branded products, agriculture technology, point of sale software, and biotechnology. The Phyto Psyche Fund targets the emerging neurowellness and brain health megatrend, focusing on psychedelic therapeutics developers, research tools organizations, and ancillary support companies. Both funds offer accredited investors professionally managed vehicles for investment in these rapidly evolving regulated industries.

Product and service2 records
1Phyto Partners Cannabis Fund
CategoryVenture Capital Fund
Description

A venture capital fund that provides debt and equity capital to privately held cannabis companies, offering accredited investors a professionally managed vehicle to participate in the cannabis market. Since June 2015, the fund has deployed capital into 30 distinct portfolio companies spanning the cannabis value chain.

2Phyto Psyche Fund
CategoryVenture Capital Fund
Description

A psychedelic-focused venture capital fund targeting early-stage operators in the neurowellness and brain health sector. The fund focuses on developers of mental health therapeutics, research tools, and ancillary companies supporting psychedelics industry growth, offering accredited investors exposure to the brain health megatrend.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Polsinelli
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Legal counsel for fund operations, providing legal guidance on regulatory compliance and fund structure matters.

phytopartners.com
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Fund administration services handling back-office operations, NAV calculations, and investor reporting.

3Rubin and Associates
Strategic tierCoreTypeImplementation/ SI/ Consulting Partner
Description

Accounting and audit services led by Gary Rubin, CPA, providing financial reporting and compliance for fund operations.

phytopartners.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Cannabis-focused venture capital firm investing across the cannabis value chain. Directly comparable as a sector-specialist VC deploying capital into cannabis and ancillary companies, competing for similar LP and deal flow.

TypeDirect peer
Description

Cannabis-focused private equity and venture capital firm. Closely comparable as a sector-dedicated fund manager with both VC and growth strategies across the cannabis industry, targeting similar portfolio construction.

TypeDirect peer
Description

Cannabis-focused hedge fund and asset manager. Directly comparable as one of the earliest institutional cannabis investment firms, also investing across the cannabis value chain with similar LP audience of accredited investors.

TypeDirect peer
Description

Cannabis-focused venture capital firm investing in ancillary, technology, and branded cannabis companies. Comparable as a sector-specialist VC with a similar thesis around ancillary and tech-enabled cannabis businesses.

TypeDirect peer
Description

Psychedelic-medicine-focused investment platform and fund manager. Highly comparable to Phyto's Psyche Fund as a dedicated psychedelic VC deploying capital into therapeutic and ancillary psychedelic companies.

TypeDirect peer
Description

Psychedelic medicine-focused venture fund. Directly comparable to Phyto Psyche as an early-stage investor in psychedelic therapeutics with similar LP audience and thesis around brain-health megatrend.

7Nosara Capital
TypeDirect peer
Description

Cannabis-focused investment firm deploying capital across public and private cannabis companies. Comparable as a specialist cannabis investment manager with diversified vehicle structures.

TypeDirect peer
Description

Cannabis-focused alternative investment manager with credit and equity strategies. Comparable as a regulated cannabis specialist with institutional-quality fund operations.

TypeBroad incumbent
Description

Large generalist venture capital firm with selective cannabis and wellness investments. Comparable as a competing capital source for cannabis deals, though Phyto is far more specialized and deeper in the vertical.

TypeBroad incumbent
Description

Prominent generalist venture capital firm with thematic exposure to psychedelic and alternative health sectors. Comparable as a competitor for psychedelic deals at larger check sizes, though not a sector specialist.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment31 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Phyto Partners

Venture Capital Fund Managementphytopartners.com

Phyto Partners is a venture capital firm managing two sector-focused funds—a Cannabis Fund (since 2015) and a Psyche Fund (psychedelics, since 2021)—that deploy debt and equity capital into privately held companies for accredited investors.

What Phyto Partners does

Phyto Partners is a Boca Raton, Florida-based venture capital firm founded in 2015 that manages two sector-focused funds serving accredited investors. The Phyto Cannabis Fund, launched in June 2015, deploys debt and equity capital into privately held companies across the cannabis value chain, including ancillary businesses in education, branded products, agriculture technology, point-of-sale software, and biotechnology. The firm has invested in approximately 30 distinct portfolio companies since inception and has produced multiple liquidity events including the public listings of Agrify (2019) and Greenlane (2020), the 2019 exit of Skylight Health, and the 2023 exit of Marijuana Doctor.

In 2021, Phyto extended its cannabis investment playbook into the emerging psychedelic and brain health sector through the launch of the Phyto Psyche Fund. The Psyche Fund targets companies developing mental health therapeutics, research tools, and ancillary services across the neurowellness value chain, with portfolio holdings spanning companies such as Wonder Sciences, Healing Maps, Mindstate Design, Muse, Healing REIT, Wondermed, and Firefly Neuro (which went public on NASDAQ under ticker AIFF in 2024).

The firm's business model is the standard venture capital model: management fees on committed capital plus carried interest on exits. Phyto differentiates through a 'more than a check' approach, providing portfolio companies with strategic support, business development assistance, introductions to customers, investors, and M&A targets, and facilitating portfolio synergies. Deal sourcing relies on proprietary industry networks and a 6-9 month due diligence framework designed for the regulatory complexity of cannabis and psychedelics. The firm operates with a lean team (1-10 employees), is structured as an LLC, and is led by Managing Partner Larry Schnurmacher with Partner Cody Shandraw, Senior Analyst Aaron Raub, Managing Director Brett Finkelstein, and CFO Gary Rubin.

Phyto Partners firmographics

Firmographics
Name
Phyto Partners
Legal name
Phyto Partners, LLC
Website
https://phytopartners.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
1–10 employees
Short description
Phyto Partners is a venture capital firm managing two sector-focused funds—a Cannabis Fund (since 2015) and a Psyche Fund (psychedelics, since 2021)—that deploy debt and equity capital into privately held companies for accredited investors.
Ownership category
akta.pro rank

Where Phyto Partners is headquartered

Location

Headquarters

HQ city
Boca Raton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Phyto Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. VC Fund Management: Phyto Partners generates revenue through management fees and carried interest (performance fees) from their venture capital funds. The firm manages the Phyto Cannabis Fund and Phyto Psyche Fund, deploying capital into portfolio companies and earning returns on successful exits.
  2. Portfolio Company Equity: The firm takes equity stakes in portfolio companies, generating returns through exits via M&A, public listings, or other liquidity events. Notable exits include Marijuana Doctor (2023), Skylight Health (2019), and Greenlane (2020 public listing), as well as Agrify public listing in 2019.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractAccredited investor VC fund participation

Go-to-market motion2 records

Distribution channels1 record

Marketing channels6 records

Phyto Partners product offering

Product offering

Core offering

Phyto Partners is a venture capital firm that manages and deploys capital from accredited investors into privately held cannabis and psychedelic companies. It operates two professionally managed funds—the Cannabis Fund (active since June 2015, with 30 portfolio companies) and the Phyto Psyche Fund (psychedelic-focused)—providing debt and equity capital, strategic support, business development, and industry network access to portfolio companies across the cannabis and emerging neurowellness value chains.

Product overview

Phyto Partners is a venture capital firm operating two distinct funds: the Cannabis Fund (launched June 2015) and the Phyto Psyche Fund (psychedelic-focused). The Cannabis Fund provides debt and equity capital to privately held cannabis companies across the value chain, including ancillary businesses in education, branded products, agriculture technology, point of sale software, and biotechnology. The Phyto Psyche Fund targets the emerging neurowellness and brain health megatrend, focusing on psychedelic therapeutics developers, research tools organizations, and ancillary support companies. Both funds offer accredited investors professionally managed vehicles for investment in these rapidly evolving regulated industries.

Differentiator

Problem solved

Functional benefit

Brands

  • Phyto Psyche Fund: Psychedelic-focused venture capital fund targeting neurowellness and brain health companies
  • Cannabis Fund

Products and services

  • Phyto Partners Cannabis Fund A venture capital fund that provides debt and equity capital to privately held cannabis companies, offering accredited investors a professionally managed vehicle to participate in the cannabis market. Since June 2015, the fund has deployed capital into 30 distinct portfolio companies spanning the cannabis value chain.
  • Phyto Psyche Fund A psychedelic-focused venture capital fund targeting early-stage operators in the neurowellness and brain health sector. The fund focuses on developers of mental health therapeutics, research tools, and ancillary companies supporting psychedelics industry growth, offering accredited investors exposure to the brain health megatrend.

Quantifiable outcome

  • 30 portfolio companies funded since June 2015
  • +2 more outcomes

Companies that use Phyto Partners

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Phyto Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Phyto Partners partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • PolsinellicoreImplementation/ SI/ Consulting PartnerLegal counsel for fund operations, providing legal guidance on regulatory compliance and fund structure matters.
  • NAV ConsultingcoreImplementation/ SI/ Consulting PartnerFund administration services handling back-office operations, NAV calculations, and investor reporting.
  • Rubin and AssociatescoreImplementation/ SI/ Consulting PartnerAccounting and audit services led by Gary Rubin, CPA, providing financial reporting and compliance for fund operations.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Phyto Partners competitors and assessment

Company assessment

Direct peers

  • Casa Verde Capital: Cannabis-focused venture capital firm investing across the cannabis value chain. Directly comparable as a sector-specialist VC deploying capital into cannabis and ancillary companies, competing for similar LP and deal flow.
  • Merida Capital Partners: Cannabis-focused private equity and venture capital firm. Closely comparable as a sector-dedicated fund manager with both VC and growth strategies across the cannabis industry, targeting similar portfolio construction.
  • Poseidon Asset Management: Cannabis-focused hedge fund and asset manager. Directly comparable as one of the earliest institutional cannabis investment firms, also investing across the cannabis value chain with similar LP audience of accredited investors.
  • Entourage Effect Capital: Cannabis-focused venture capital firm investing in ancillary, technology, and branded cannabis companies. Comparable as a sector-specialist VC with a similar thesis around ancillary and tech-enabled cannabis businesses.
  • Iter Investments: Psychedelic-medicine-focused investment platform and fund manager. Highly comparable to Phyto's Psyche Fund as a dedicated psychedelic VC deploying capital into therapeutic and ancillary psychedelic companies.
  • Palo Santo: Psychedelic medicine-focused venture fund. Directly comparable to Phyto Psyche as an early-stage investor in psychedelic therapeutics with similar LP audience and thesis around brain-health megatrend.
  • Nosara Capital: Cannabis-focused investment firm deploying capital across public and private cannabis companies. Comparable as a specialist cannabis investment manager with diversified vehicle structures.
  • Tuatara Capital: Cannabis-focused alternative investment manager with credit and equity strategies. Comparable as a regulated cannabis specialist with institutional-quality fund operations.

Broad incumbents

  • Bessemer Venture Partners: Large generalist venture capital firm with selective cannabis and wellness investments. Comparable as a competing capital source for cannabis deals, though Phyto is far more specialized and deeper in the vertical.
  • Founders Fund: Prominent generalist venture capital firm with thematic exposure to psychedelic and alternative health sectors. Comparable as a competitor for psychedelic deals at larger check sizes, though not a sector specialist.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Phyto Partners social profiles

Digital presence

Phyto Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Phyto Partners leadership team

Management profile

Number of profiles

Profiles5 records

Phyto Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Phyto Partners M&A and investment

M&A and investment

M&A

Investments31 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Phyto Partners

What does Phyto Partners do?

Phyto Partners is a venture capital firm that manages and deploys capital from accredited investors into privately held cannabis and psychedelic companies. It operates two professionally managed funds—the Cannabis Fund (active since June 2015, with 30 portfolio companies) and the Phyto Psyche Fund (psychedelic-focused)—providing debt and equity capital, strategic support, business development, and industry network access to portfolio companies across the cannabis and emerging neurowellness value chains.

Is Phyto Partners a public or private company?

Phyto Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Phyto Partners founded?

Phyto Partners was founded in 2015. It employs 1 to 10 people.

Where is Phyto Partners based?

Phyto Partners is headquartered in Boca Raton, United States, in the North America region.

How does Phyto Partners make money?

Two revenue lines are on record. VC Fund Management is the primary driver. The others are portfolio Company Equity.

Who are Phyto Partners's main competitors?

Direct peers on record are Casa Verde Capital, Merida Capital Partners, Poseidon Asset Management, Entourage Effect Capital, Iter Investments, Palo Santo, Nosara Capital and Tuatara Capital. Broad incumbents are Bessemer Venture Partners and Founders Fund.

Does Phyto Partners have an API?

No public API is recorded for Phyto Partners.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business InsiderA cannabis VC who made 292% on his first fund is raising a fresh $25 million to bet on psychedelicsLarry Schnurmacher of Phyto Partners is raising up to $25 million for a fourth fund focused on psychedelics, opening October 1. He cites the cannabis industry's maturity and cites his first fund's 292% return. The fund targets biotech, clinics, and tech firms in the space.PR NewswirePhyto Partners Bags Its First Unicorn With Canna-Tech Company GreenbitsDutchie, a leading cannabis tech platform, has acquired Greenbits and LeafLogix in a merger deal valuing the combined entity at $1.7 billion, led by Tiger Global with participation from Dragoneer, DFJ Growth, and other investors. The acquisition marks Phyto Partners' first unicorn exit, as their portfolio company Greenbits joins Dutchie's cannabis retail technology suite. Industry observers note that traditional venture capital firms are increasingly entering the cannabis ancillary space, a trend expected to drive valuations higher.Business InsiderSee the 13-slide presentation that a Facebook engineer and a Wall Street analyst used to convince investors to bet on a new kind of software tool for the cannabis industryCanix, a cannabis compliance software company, closed a $2.5 million seed round led by Phyto Partners and Floret Ventures. The San Francisco-based firm reports 300 US clients and 12% monthly revenue growth. It plans to expand geographically and enhance forecasting modules.PR NewswirePhyto Partners Launches Phyto III Cannabis Focused Venture Capital FundPhyto Partners announced the launch of Phyto III, its third cannabis-focused private equity fund, targeting $50 million from accredited investors. The fund will leverage the firm's early-mover advantage and industry expertise to invest in early and later-stage privately held companies addressing critical challenges in the cannabis sector. Managing Partner Larry Schnurmacher cited an estimated $100 billion annual revenue opportunity and described the current valuation reset as an attractive entry point for new investments.BenzingaThe Top VC Investors In CannabisPitchBook released its 2019 list of top cannabis VC firms, noting $1.2B in venture capital, with $500M already invested in 2019. Phyto Partners led with nine deals, while Pax Labs closed a $420M equity round. The article cites federal law as a barrier, with the SAFE Banking Act potentially easing it.PR NewswireDigital Marketing Expert Joins Phyto Partner's Advisory BoardPhyto Partners, a Cannabis Investment Fund, announced that Jeff Herzog has joined its Board of Advisors. Herzog is a digital marketing pioneer who previously founded iCrossing, which was acquired by Hearst Magazines for $325 million in 2010, and ZOG Digital, which was acquired by Investis Digital in 2017. Phyto Partners, founded in 2015, invests in ancillary cannabis businesses and currently has over 20 portfolio companies.PR NewswireLucid Green Sets the Standard by Launching the Industry's First "Direct to Consumer" Data Platform, Enabling Consumers to Have a Safe, Consistent and Enjoyable Cannabis ExperienceLucid Green Inc., a cannabis technology platform, has launched an industry-first direct-to-consumer data platform designed to connect consumers and budtenders with cannabis brands through IoT, blockchain, and token technologies. The company closed an oversubscribed seed funding round of slightly more than $1 million, led by XDL Ventures and Phyto Partners, to develop the platform which is now live in Colorado and Washington State through partnerships with incredibles, 14'er, and Ionic product brands.NewswirePhyto Partners Closes on $14 Million for 2nd Cannabis Venture Capital FundPhyto Partners closed $14 million in capital commitments for its second cannabis venture capital fund, Phyto II. The fund is investing in Marijuana Doctor and Flowhub, with Phyto as lead investor in Marijuana Doctor. Capital deployment has begun.PYMNTS.comWurk Raises Funds For Marijuana SoftwareWurk, a marijuana software startup, raised $3.2 million from Poseidon Asset Management, Phyto Partners, and others. The funds will support its legal payroll and HR services for cannabis businesses, with plans to hire a CTO and COO.AlleyWatchThis NYC Startup Just Raised $3M to Be the Highway for Cannabis EcommerceLeafLink, a cannabis ecommerce platform, raised a $3M seed round led by Lerer Hippeau Ventures. The company, serving 800 dispensaries, reports over $65M in annual sales and plans to launch in Nevada, Oregon, and California.